Arkis BioSciences® showcases successful clinical introduction of CerebroFlo™ at the 2018 American Association of Neurological Surgeons

Arkis BioSciences® exhibited at the 2018 American Association of Neurological Surgeons, announcing a successful clinical introduction of Endexo® Technology to neurosurgical use with the new and exclusive CerebroFlo™ EVD Catheter.
“Arkis’ CerebroFlo EVD catheter is a major step forward in next generation clinical technology for neurology and neuro-intensive care. We are excited to have transitioned from the laboratory phase to clinical use for CerebroFlo and for patients and providers to realize the potential benefits Endexo has to offer.” said Chad Seaver, President and CEO of Arkis BioSciences. “We look forward to further proliferating Endexo into other CNS catheters, such as subdural drains and, particularly, shunt catheters, with a vision toward reducing revision surgeries. We are concurrently investigating the Endexo molecules’ ability to further inhibit biofilm formation toward reducing bacterial colonization, which can often lead to infection.”

Contact Us

© 2019 Integra LifeSciences.  All rights reserved.   |   Privacy   |   Terms of Use

Go to top